-+ 0.00%
-+ 0.00%
-+ 0.00%

On November 18, Kangfang Biotech and Iwasi's overseas partner Summit Therapeutics jointly announced that Kangfang Biotech's global first tumor immunity 2.0 cornerstone drug, evasil contrast valiumab, as a consolidation treatment for locally advanced, unresectable non-small cell lung cancer with no disease progression after receiving radical platinum-containing simultaneous chemoradiotherapy, has begun an international multi-center registration phase III study.

智通财经·11/19/2026 01:09:00
语音播报
On November 18, Kangfang Biotech and Iwasi's overseas partner Summit Therapeutics jointly announced that Kangfang Biotech's global first tumor immunity 2.0 cornerstone drug, evasil contrast valiumab, as a consolidation treatment for locally advanced, unresectable non-small cell lung cancer with no disease progression after receiving radical platinum-containing simultaneous chemoradiotherapy, has begun an international multi-center registration phase III study.